ROCHE MOCLOBEMIDE MAO-A INHIBITOR IS ANTIDEPRESSANT OUTLICENSE CANDIDATE FOR U.S. MARKET; REVERSIBLE, MAO-A SELECTIVE COMPOUND COULD AVOID DIET PROBLEMS

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".